David Schenkein joined Agios Pharmaceuticals in August 2009 as the Chief Executive Officer. Prior to joining Agios, Dr. Schenkein was the Senior Vice President, Clinical Hematology/Oncology at Genentech, Inc. in San Francisco where he was responsible for leading the medical and scientific strategies for their BioOncology portfolio. He has been a Medical Oncologist and Hematologist for over 20 years and while in San Francisco was an Adjunct Clinical Professor of Medicine Oncology at Stanford University School of Medicine.
Prior to joining Genentech, Dr. Schenkein spent 17 years in academic and clinical medicine as an attending physician in Hematology Oncology at the Tufts-New England Medical Center in Boston, where he was an associate professor and held the position of director of the Cancer Center. From 2001-2006, he worked at Millennium Pharmaceuticals where he served as the Senior Vice President of Clinical Research, overseeing the clinical development of Velcade, a first-in class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. Dr. Schenkein holds a B.A. in Chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.